Brad Nawa is a seasoned professional in the biotechnology and pharmaceutical sectors, currently serving as Director West at Alamar Biosciences, Inc. since February 2024. Prior to this role, Nawa held key positions at Sengenics, where as Director-Commercial, contributions were made towards precision medicine and autoantibody biomarker discovery. Experience also includes a tenure at Epic Sciences, focusing on high-definition diagnostic tests for cancer, and a role at Labcorp Drug Development managing business development for translational biomarkers and companion diagnostics. Earlier career highlights feature managerial roles at Olink Proteomics and Meso Scale Discovery, emphasizing innovative approaches in biomarker analysis and drug discovery. Nawa began the career in the pharmaceutical sector as a Key Account Manager at BD Biosciences after earning a BA in Chemistry Math, an MS in Biology, and an MBA from Indiana University's Kelley School of Business.